Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+/HER2−metastatic breast cancer patients: a multicenter study (YOUNGBC-28)
Background: In recent years, the combination of CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET) has emerged as the standard first-line treatment for hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2−) metastatic breast cancer (MBC) patients. However,...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-12-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359241302018 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850114790990544896 |
|---|---|
| author | Yifan Chen Yizhao Xie Die Sang Ning Xie Xinhua Han Yanxia Zhao Juanjuan Li Jian Yue Peng Yuan Biyun Wang |
| author_facet | Yifan Chen Yizhao Xie Die Sang Ning Xie Xinhua Han Yanxia Zhao Juanjuan Li Jian Yue Peng Yuan Biyun Wang |
| author_sort | Yifan Chen |
| collection | DOAJ |
| description | Background: In recent years, the combination of CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET) has emerged as the standard first-line treatment for hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2−) metastatic breast cancer (MBC) patients. However, the comparison between the efficacy of CDK4/6i has been poorly explored before. Moreover, it remains unclear about the optimal choice of CDK4/6i in the first-line treatment for HR+/HER2− MBC patients in Asian, especially Chinese populations. Objectives: Our study aims to compare the efficacy of three CDK4/6i widely used in the Chinese population (palbociclib, abemaciclib, and dalpiciclib) in the real world. Design: From 2020 to 2023, the medical records of patients diagnosed with HR+/HER2− MBC were retrospectively assessed in seven institutions in China. Patients who received first-line palbociclib, abemaciclib, or dalpiciclib plus ET were included. Methods: Demographic and clinical data were retrospectively collected and analyzed. Real-world progression-free survival (rwPFS), overall survival (OS), and objective response rate were used to analyze the clinical outcome. Results: In total, 209 HR+/HER2− MBC patients were eligible for this study. Eighty-eight (42.1%), 79 (37.8%), and 42 (20.1%) patients were administered first-line palbociclib, abemaciclib, or dalpiciclib plus ET. The overall median rwPFS was 19 months, with no significant difference between these three CDK4/6i ( p = 0.84). The results were similar even after propensity score matching. The median OS was not reached. Cox univariate and multivariate regression analysis identified that higher KI67 index, liver metastasis, and primary endocrine resistance were independent risk factors for rwPFS in patients with initial CDK4/6i plus ET. Conclusion: This study presents a comparison of the real-world efficacy between three CDK4/6i widely used in the Chinese population. Palbociclib, abemaciclib, and dalpiciclib demonstrated comparable efficacy in Chinese patients with advanced HR+/HER2− MBC. Trial registration: ClinicalTrials.gov identifier: NCT06344780. |
| format | Article |
| id | doaj-art-17a987e726a34ae2a5a08d06db1efe14 |
| institution | OA Journals |
| issn | 1758-8359 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj-art-17a987e726a34ae2a5a08d06db1efe142025-08-20T02:36:45ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592024-12-011610.1177/17588359241302018Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+/HER2−metastatic breast cancer patients: a multicenter study (YOUNGBC-28)Yifan ChenYizhao XieDie SangNing XieXinhua HanYanxia ZhaoJuanjuan LiJian YuePeng YuanBiyun WangBackground: In recent years, the combination of CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET) has emerged as the standard first-line treatment for hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2−) metastatic breast cancer (MBC) patients. However, the comparison between the efficacy of CDK4/6i has been poorly explored before. Moreover, it remains unclear about the optimal choice of CDK4/6i in the first-line treatment for HR+/HER2− MBC patients in Asian, especially Chinese populations. Objectives: Our study aims to compare the efficacy of three CDK4/6i widely used in the Chinese population (palbociclib, abemaciclib, and dalpiciclib) in the real world. Design: From 2020 to 2023, the medical records of patients diagnosed with HR+/HER2− MBC were retrospectively assessed in seven institutions in China. Patients who received first-line palbociclib, abemaciclib, or dalpiciclib plus ET were included. Methods: Demographic and clinical data were retrospectively collected and analyzed. Real-world progression-free survival (rwPFS), overall survival (OS), and objective response rate were used to analyze the clinical outcome. Results: In total, 209 HR+/HER2− MBC patients were eligible for this study. Eighty-eight (42.1%), 79 (37.8%), and 42 (20.1%) patients were administered first-line palbociclib, abemaciclib, or dalpiciclib plus ET. The overall median rwPFS was 19 months, with no significant difference between these three CDK4/6i ( p = 0.84). The results were similar even after propensity score matching. The median OS was not reached. Cox univariate and multivariate regression analysis identified that higher KI67 index, liver metastasis, and primary endocrine resistance were independent risk factors for rwPFS in patients with initial CDK4/6i plus ET. Conclusion: This study presents a comparison of the real-world efficacy between three CDK4/6i widely used in the Chinese population. Palbociclib, abemaciclib, and dalpiciclib demonstrated comparable efficacy in Chinese patients with advanced HR+/HER2− MBC. Trial registration: ClinicalTrials.gov identifier: NCT06344780.https://doi.org/10.1177/17588359241302018 |
| spellingShingle | Yifan Chen Yizhao Xie Die Sang Ning Xie Xinhua Han Yanxia Zhao Juanjuan Li Jian Yue Peng Yuan Biyun Wang Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+/HER2−metastatic breast cancer patients: a multicenter study (YOUNGBC-28) Therapeutic Advances in Medical Oncology |
| title | Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+/HER2−metastatic breast cancer patients: a multicenter study (YOUNGBC-28) |
| title_full | Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+/HER2−metastatic breast cancer patients: a multicenter study (YOUNGBC-28) |
| title_fullStr | Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+/HER2−metastatic breast cancer patients: a multicenter study (YOUNGBC-28) |
| title_full_unstemmed | Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+/HER2−metastatic breast cancer patients: a multicenter study (YOUNGBC-28) |
| title_short | Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+/HER2−metastatic breast cancer patients: a multicenter study (YOUNGBC-28) |
| title_sort | real world comparison of palbociclib abemaciclib and dalpiciclib as first line treatments for chinese hr her2 metastatic breast cancer patients a multicenter study youngbc 28 |
| url | https://doi.org/10.1177/17588359241302018 |
| work_keys_str_mv | AT yifanchen realworldcomparisonofpalbociclibabemaciclibanddalpiciclibasfirstlinetreatmentsforchinesehrher2metastaticbreastcancerpatientsamulticenterstudyyoungbc28 AT yizhaoxie realworldcomparisonofpalbociclibabemaciclibanddalpiciclibasfirstlinetreatmentsforchinesehrher2metastaticbreastcancerpatientsamulticenterstudyyoungbc28 AT diesang realworldcomparisonofpalbociclibabemaciclibanddalpiciclibasfirstlinetreatmentsforchinesehrher2metastaticbreastcancerpatientsamulticenterstudyyoungbc28 AT ningxie realworldcomparisonofpalbociclibabemaciclibanddalpiciclibasfirstlinetreatmentsforchinesehrher2metastaticbreastcancerpatientsamulticenterstudyyoungbc28 AT xinhuahan realworldcomparisonofpalbociclibabemaciclibanddalpiciclibasfirstlinetreatmentsforchinesehrher2metastaticbreastcancerpatientsamulticenterstudyyoungbc28 AT yanxiazhao realworldcomparisonofpalbociclibabemaciclibanddalpiciclibasfirstlinetreatmentsforchinesehrher2metastaticbreastcancerpatientsamulticenterstudyyoungbc28 AT juanjuanli realworldcomparisonofpalbociclibabemaciclibanddalpiciclibasfirstlinetreatmentsforchinesehrher2metastaticbreastcancerpatientsamulticenterstudyyoungbc28 AT jianyue realworldcomparisonofpalbociclibabemaciclibanddalpiciclibasfirstlinetreatmentsforchinesehrher2metastaticbreastcancerpatientsamulticenterstudyyoungbc28 AT pengyuan realworldcomparisonofpalbociclibabemaciclibanddalpiciclibasfirstlinetreatmentsforchinesehrher2metastaticbreastcancerpatientsamulticenterstudyyoungbc28 AT biyunwang realworldcomparisonofpalbociclibabemaciclibanddalpiciclibasfirstlinetreatmentsforchinesehrher2metastaticbreastcancerpatientsamulticenterstudyyoungbc28 |